Active	Status	Sponsor type	Region	Phase	Filter
7 Active 8 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Blakeley, Jaishri O
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)	Completed	2	199	US	NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel	NFlection Therapeutics, Inc.	Cutaneous Neurofibroma, Neurofibromatosis 1	10/23	10/23
INTUITT-NF2, NCT04374305: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis	Active, not recruiting	2	100	US	Brigatinib, Alunbrig, Neratinib, Nerlynx	Scott R. Plotkin, MD, PhD, Takeda, The Children's Tumor Foundation, National Comprehensive Cancer Network	Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma	12/29	12/30
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas	Recruiting	1/2	30	US	Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a	SignPath Pharma, Inc., Avance Clinical Pty Ltd.	Glioblastoma	02/26	05/27
NCT04465643: Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor	Recruiting	1	18	US	Nivolumab, Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb	Nerve Sheath Tumors	06/25	08/26
Roberts, Joshua
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)	Completed	2	199	US	NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel	NFlection Therapeutics, Inc.	Cutaneous Neurofibroma, Neurofibromatosis 1	10/23	10/23
Mirda, NCT06159166: metinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).	Recruiting	1/2	24	US	Mirdametinib	Johns Hopkins University, Neurofibromatosis Therapeutic Acceleration Program	NF1, Cutaneous Neurofibroma, Monotherapy	11/27	11/28
SGNS70-101, NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies	Recruiting	1	140	Europe, US	SEA-CD70, azacitidine, VIDAZA	Seagen Inc.	Myelodysplastic Syndrome, Acute Myeloid Leukemia	12/24	11/26